Follow
Acute Myeloid Leukemia
Acute myeloid leukemia, or AML, is a type of cancer that affects the bone marrow and blood. AML usually begins in cells that turn into white blood cells, but it can start in other blood-forming cells, as well.
MAY 31, 2023 | 11:00 AM
Date: May 31, 2023 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CET) Single-cell genomics has facilitated the understanding of mechanisms involved in various biological processes such as tumor...
MAR 22, 2023 | 6:00 AM
We have developed an electronic method to screen cells for their phenotypic profile, which we call Node-Pore Sensing (NPS). NPS involves using a four-terminal measurement to measure the modu...
FEB 09, 2021 | 8:00 AM
DATE: February 09, 2021 TIME: 08:00am PST Flow cytometry immunophenotyping has become one of the mainstream applications for the diagnosis and classification of several hematologic neoplasms...
OCT 22, 2020 | 12:25 PM
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
OCT 22, 2020 | 12:25 PM
Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) processes and acute myeloid leuke...
OCT 07, 2020 | 10:30 AM
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
OCT 01, 2020 | 11:00 AM
Date: October 1, 2020 Time: 10:00am (PTD), 1:00pm (EDT) Cancer cells rely on altered metabolism to support their proliferation. We performed a CRISPR/Cas9 functional genomic screen targeting...
SEP 23, 2020 | 6:30 AM
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
MAY 20, 2020 | 1:15 PM
Background: Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological malignancy. Despite recent advancements in the treatment of AML, approximately 50% of pat...
MAY 20, 2020 | 11:45 AM
Tumor phenotypes are dictated not only by the neoplastic cell component, but also by the tumor microenvironment (TME), which is inherently immuno-suppressive, is equipped to hamper effector...
